Ascendis Pharma A/S
ASND
129 hedge funds and large institutions have $4.44B invested in Ascendis Pharma A/S in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 39 reducing their positions, and 20 closing their positions.
490% more call options, than puts
Call options by funds: $109M | Put options by funds: $18.5M
33% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 39
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 132 → 129 (-3)
5.95% less ownership
Funds ownership: 102.94% → 97% (-5.9%)
13% less funds holding in top 10
Funds holding in top 10: 16 → 14 (-2)
19% less capital invested
Capital invested by funds: $5.49B → $4.44B (-$1.04B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$75.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$66.6M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$61M |
| 4 |
Janus Henderson Group
London,
|
+$36.4M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$237M |
| 2 |
PA
Perceptive Advisors
New York
|
-$54.5M |
| 3 |
LCM
Lakewood Capital Management
New York
|
-$51.1M |
| 4 |
VMI
VHCP Management II
New York
|
-$30.1M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$22.3M |
ASND Hedge Fund Activity: Q3 2019 in Review
129 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2019, worth a combined $4.44B — down 19% from $5.49B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ASND and 19 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 52 added.
The largest buyer was Wellington Management Group, adding an estimated $75.2M. The largest seller was Vivo Capital, exiting entirely with an estimated $237M sold.
- 129 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2019, down from 132 in Q2 2019.
- Funds reported $4.44B of Ascendis Pharma A/S stock for Q3 2019, down 19% quarter-over-quarter.
- 19 funds opened new Ascendis Pharma A/S positions in Q3 2019 and 20 closed out, a net change of -1 holder.
- The largest Ascendis Pharma A/S buyer in Q3 2019 was Wellington Management Group, an estimated $75.2M added.
- The largest Ascendis Pharma A/S seller in Q3 2019 was Vivo Capital, an estimated $237M sold.
Based on aggregated 13F filings for Q3 2019.